Zachery Schramm, ResearchAssistant, Division of Internal Medicine University of Washington HarborviewMedical Center
Office-based buprenorphine medication treatment is a viableoption for patients living with opioid use disorders (OUDs). Yet, initiallymany struggle with medication adherence and clinic program policy adherence leadingto continued substance use and unfavorable clinical outcomes. In the current healthcare technology boom,technologies supporting medication adherence present an opportunity to improvepatient and clinic successes. The Trial of Adherence Application forBuprenorphine treatment (TAAB) Study is a pilot RCT currently enrolling upwardsof 80 patients, with 40 randomized to receive a mobile health intervention. Theintervention is a mobile app using the front facing camera of smartphones torecord asynchronous medication adherence videos, known as video directlyobserved therapy (video DOT). Earlier studies showed favorable interest amongpatients for such tools which could provide structure and accountability. TAABStudy intervention participants are asked to upload daily medication adherencevideos over the course of 3 months. With a potential total of 3,360 videos, theentire cohort of intervention participants are submitting 31.87% of videos, yetthe individual adherence to video submission ranges from 0-88%. Thus theresults are showing variability in usage and uptake among this patientpopulation furthering the potential benefits and drawbacks of this newlydeveloped mHealth technology.